Project Name: Tower Family Healthcare Heart failure with reduced ejection fraction (HFrEF) audit, therapy review, medicines optimisation and functional capacity assessment
Project Summary:
The CWP will fund a Clinical Pharmacist to review and audit the CW Partner’s databases, to identify sub optimally treated Patients that require a review, medicines optimisation and where required a clinic review. For complex cases, there are existing multidisciplinary team (MDT) meetings with a Consultant Cardiologist, Clinical Pharmacist, and CVD Nurse, to decide on best practice for the patient. The CWP, led by Clinical Pharmacist (Band 9) will upskill the team of clinical pharmacists to ensure continuity of service when the CWP ends. Resulting in upskilling of cardiovascular disease (CVD) identification and management in the primary care network (PCN).
Planned Milestones:
Project kick-off meeting
Data cleanse patient medical notes from four surgeries
Confirm ready to start medicines optimisation clinic/reviews
Reviews at month(s) 3, 6, 9 and 12
Project write up, outcomes report
- Project wrap-up meeting
Expected Benefits:
Patients
Improved access to diagnosis and treatment
Medicine optimisation leading to better outcomes
More equitable and consistent care and access to care
Enhanced experience for patients and their carers who live with CVD
Longer term raised awareness will lead to quicker diagnosis and additional avoided admissions
These are vulnerable patients with high mortality and morbidity rates
Patients could have more optimised care closer to home and access to specialist in the community
CW Partner
Integrated approach to CVD care delivery
CW Partner is upskilled to allow for the appropriate assessment and management of CVD patients
Increase levels of accurate diagnosis of HF by achieving 0.96% LVSD Prevalence (66% NICOR projection of HF register)
Increase the overall quality of care and improve equity of access to primary and specialist care for patients with CVD
Improve patient flow and reduce total number of inpatient bed days due to HF
Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events
Easier access to lipid management care closer to home in the Primary Care setting
Novartis
Better understanding of overall customers’ and patients’ needs
Improved access to and use of NICE approved medications (including Novartis medicines) in appropriate patients
Ethical, professional, and transparent relationship between Novartis and the NHS
Start Date & Duration: September 2023 for 14 months
UK2307208970